Stockscreener 앱 받기
0.8814
3.14%
-0.0286
전일 마감가:
$0.91
열려 있는:
$0.9212
하루 거래량:
21,200
Relative Volume:
0.17
시가총액:
$31.35M
수익:
-
순이익/손실:
$-9.16M
주가수익비율:
-1.5463
EPS:
-0.57
순현금흐름:
$-8.75M
1주 성능:
-11.86%
1개월 성능:
-6.30%
6개월 성능:
-13.59%
1년 성능:
-26.55%
1일 변동 폭
$0.8602
$0.97
1주일 범위
$0.8001
$1.03
52주 변동 폭
$0.7736
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.8814 | 31.35M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World
H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa
Revolutionary Pancreatic Cancer Treatment Update: RenovoRx CEO Presents Latest Clinical Trial Results - Stock Titan
H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com India
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RenovoRx projects growth with new orders and clinical trial - Investing.com
RenovoRx Hits Major Milestone: First Revenue from Cancer Device as Phase 3 Trial Nears Key Analysis - Stock Titan
RenovoRx, Inc. SEC 10-K Report - TradingView
RenovoRx Delays Yearly Report Filing - TipRanks
Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Business Wire
RenovoRx (RNXT) to Release Earnings on Monday - Defense World
HC Wainwright Estimates RenovoRx FY2024 Earnings - Defense World
RenovoRx Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting - BioSpace
Breakthrough: RenovoRx's Pancreatic Cancer Treatment Shows Promise with Reduced Systemic Exposure - Stock Titan
RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of RenovoRx (RNXT) with Buy Recommendation - Nasdaq
HC Wainwright Initiates Coverage on RenovoRx With Buy Rating, $3 Price Target - MarketScreener
RenovoRx honored for cancer treatment research By Investing.com - Investing.com South Africa
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting - BioSpace
RenovoRx honored for cancer treatment research - Investing.com
RenovoRx (NASDAQ:RNXT) Stock Price Up 11.5% – Should You Buy? - Defense World
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET - Business Wire
RenovoRx Reveals Commercial Milestones and Phase 3 Trial Updates for Revolutionary Pancreatic Cancer Treatment - Stock Titan
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 - Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 - Business Wire
RenovoRx launches public stock offering - MSN
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - BioSpace
with Several New Purchase Orders, Including Customer Reorders - Business Wire
Can RenovoRx's Premium-Priced Cancer Device Deliver on its $400M Market Potential? - Stock Titan
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - BioSpace
RenovoRx Announces $10.9 Million Public Offering of Common Stock - Defense World
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
RenovoRx (RNXT) Lands Major $12.1M Healthcare Investor Backing for Cancer Treatment Launch - Stock Titan
A better buy-in window may exist right now for RenovoRx Inc (RNXT) - SETE News
Closing Figures: RenovoRx Inc (RNXT)’s Negative Finish at 1.16, Down -20.55 - The Dwinnex
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
RenovoRx Inc (RNXT) Stock: A Year of Decreases and Increases - The InvestChronicle
RenovoRx Inc (RNXT) Stock: Tracking the Weekly Performance - The News Heater
RenovoRx 11.52M share Spot Secondary priced at $1.05 - MSN
RenovoRx (NASDAQ:RNXT) Stock Price Down 20.5% – Should You Sell? - Defense World
RenovoRx announces proposed public offering - MSN
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Po - GuruFocus.com
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement - Yahoo Finance
RenovoRx prices public offering to raise $12.1M - MSN
RenovoRx launches public stock offering By Investing.com - Investing.com Nigeria
RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr - Nasdaq
RenovoRx Secures Critical $12.1M Funding: Phase III Cancer Study Gets Green Light - StockTitan
Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock - Marketscreener.com
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
RenovoRx Raises Fresh Capital to Accelerate Revolutionary Cancer Treatment Platform - StockTitan
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):